Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 04/07 01:35:02 pm
89.825 EUR   +0.20%
04/06CARL ZEISS MEDITEC AG : Gets a Buy rating from Deutsche Bank
MD
04/03CARL ZEISS MEDITEC : Zeiss-Revenue in second quarter
AQ
04/03CARL ZEISS MEDITEC AG : Kepler Chevreux remains a Sell rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec : achieves significant increase in sales and earnings in fiscal year 2018/19

share with twitter share with LinkedIn share with facebook
share via e-mail
12/06/2019 | 03:21am EDT
In fiscal year 2018/19, Carl Zeiss Meditec generated revenue of €1,459.3m, resulting in an increase of 13.9% (adjusted for currency effects: +11.7%) compared with the same period of the prior year (prior year: €1,280.9m). Earnings before interest and taxes (EBIT) rose significantly, to €264.7m (prior year: €197.1m). The EBIT margin was 18.1% (prior year: 15.4%).

"This was a record year for Carl Zeiss Meditec AG, to which all business units and regions contributed," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.
Ophthalmology and Microsurgery continue to grow
The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 14.5 percent in the fiscal year 2018/19 (adjusted for currency effects: +12.4 percent), to €1,068.6m, compared with €933.2m in the same period of the prior year. Significant drivers of this revenue growth were once again laser systems for vision correction as well as devices and consumables for cataract surgery.

Revenue in the Microsurgery SBU grew by 12.4 percent (adjusted for currency effects: +9.7 percent), to €390.7m, compared with €347.6m in the same period of the prior year. Sales of visualization systems for neurosurgeons, for the treatment of tumors and vascular diseases, continued to develop well.
Solid growth in EMEA and APAC
Revenue in the EMEA region increased by 10.3 percent in fiscal year 2018/19 (adjusted for currency effects: +10.7 percent), to €417.1m (prior year: €378.1m). The core markets Germany, France and the UK achieved good revenue growth.

Revenue in the Americas region also increased, reaching a new all-time high of €442.5m (prior year: €406.5m). This growth amounted to +8.9 percent (adjusted for currency effects: +3.9 percent).

The APAC region recorded revenue growth of 20.8 percent (adjusted for currency effects: +19.0 percent), to €599.7m (prior year: €496.3m). Once again, the largest contributions to growth came from China and South Korea. Japan also performed well.
The operating result (EBIT) increased to €264.7m in fiscal year 2018/19 (prior year: €197.1m). This significant increase is primarily due to a positive development of the product mix, accompanied by a slight decline in operating cost ratios. The EBIT margin increased from 15.4 percent to 18.1 percent. Adjusted for special effects, the increase amounted to 18.5 percent (prior year: 15.7 percent). Earnings per share increased to € 1.79 from €1.41 in the prior year.

Carl Zeiss Meditec expects to be able to grow faster than the underlying markets again in fiscal year 2019/20. The EBIT margin is expected to be in a range from 17 to 19 percent. Significant additional investments in research and development and in sales and marketing are already factored into this outlook.

Dr. Ludwin Monz continued: "Our markets are attractive and offer significant opportunities for growth. We want to seize these opportunities and create further value in the long term. This will require substantial investments in certain areas, particularly in development and sales presence, which we already started in fiscal year 2018/19. In the medium term, we want to secure the level of earnings we have already achieved and generate an EBIT margin that is sustainably above 18%."
Revenue by strategic business unit
All figures in €m

12 months
2018/19

12 months
2017/18

Change from
prior year

Change from
prior year*

Ophthalmic Devices

1,068.6
933.2
+14.5%
+12.4%
Microsurgery

390.7
347.6
+12.4%
+9.7%
Overall group

1,459.3

1,280.9

+13.9%

+11.7%
*adjusted for currency effects

Revenue by region
All figures in €m

12 months
2018/19

12 months
2017/18

Change from
prior year

Change from
prior year*

EMEA
417.1
378.1
+10.3%
+10.7%
Americas
442.5
406.5
+8.9%
+3.9%
APAC

599.7
496.3
+20.8%
+19.0%
Overall group

1,459.3
1,280.9
+13.9%
+11.7%

*adjusted for currency effects

Press Contact
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.com

Disclaimer

Carl Zeiss Meditec AG published this content on 06 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 December 2019 08:20:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CARL ZEISS MEDITEC AG
04/06CARL ZEISS MEDITEC AG : Gets a Buy rating from Deutsche Bank
MD
04/03CARL ZEISS MEDITEC : Zeiss-Revenue in second quarter
AQ
04/03CARL ZEISS MEDITEC AG : Kepler Chevreux remains a Sell rating
MD
04/02CARL ZEISS MEDITEC AG : Revenue in second quarter of 2019/20 stagnating - Furthe..
EQ
03/27CARL ZEISS MEDITEC AG : Hauck & Aufhauser remains Neutral
MD
03/26CARL ZEISS MEDITEC AG : Release according to Article 40, Section 1 of the WpHG [..
EQ
03/26CARL ZEISS MEDITEC AG : Berenberg gives a Neutral rating
MD
03/25CARL ZEISS MEDITEC AG : Ex-dividend day for final dividend
FA
03/23CARL ZEISS MEDITEC AG : Release according to Article 40, Section 1 of the WpHG [..
EQ
03/18CARL ZEISS MEDITEC AG : Postponement of the Annual General Meeting 2020 in the c..
AQ
More news
Financials (EUR)
Sales 2020 1 494 M
EBIT 2020 249 M
Net income 2020 177 M
Finance 2020 634 M
Yield 2020 0,84%
P/E ratio 2020 41,5x
P/E ratio 2021 34,4x
EV / Sales2020 4,61x
EV / Sales2021 4,01x
Capitalization 7 513 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 102,27  €
Last Close Price 84,00  €
Spread / Highest target 66,7%
Spread / Average Target 21,8%
Spread / Lowest Target -29,8%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors